Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.

@article{Wagner2020RopeginterferonAF,
  title={Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.},
  author={Sandro Wagner and Thomas Melchardt and Richard Greil},
  journal={Drugs of today},
  year={2020},
  volume={56 3},
  pages={
          195-202
        }
}
Ropeginterferon alfa-2b is a novel mono-PEGylated alfa interferon. It is the first interferon approved for the treatment of patients with polycythemia vera (PV) and the first and only approved treatment for PV independent of previous hydroxyurea exposure. In contrast to other interferons, the drug has to be subcutaneously injected every 2 weeks only, with intervals of 4 weeks being possible after prolonged use. It is generally well tolerated and can lead to deep molecular responses. In this… Expand
A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera
TLDR
Clinical data suggests that the compound may provide a disease-modifying option for PV patients with asymptomatic splenomegaly, representing a significant improvement compared to conventional cytoreductive therapies. Expand
Pharmacokinetics and Pharmacodynamics of Novel Long-Acting Ropeginterferon Alfa-2b in Healthy Chinese Subjects
  • Yi-Wen Huang, Chan-Yen Tsai, +6 authors Mei-xia Wang
  • Medicine
  • Advances in Therapy
  • 2021
TLDR
Ropeginterferon alfa-2b is safe and well tolerated after a single subcutaneous injection up to 270 mcg in healthy Chinese and the pharmacokinetics, pharmacodynamics and safety profiles and safety of the product are evaluated. Expand
Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration
TLDR
Ropeginterferon alfa-2b up to 300 µg was safe and well tolerated, with no unexpected safety findings based on previous experiences with ropeginterferonAlfa- 2b and other forms of interferon. Expand
The Role of Neutrophilic Granulocytes in Philadelphia Chromosome Negative Myeloproliferative Neoplasms
TLDR
The molecular biology underlying myeloproliferative neoplasms is discussed and the central role of leukocytosis and, specifically, neutrophilic granulocytes is pointed out in this group of disorders. Expand
Circulating Type I Interferon Levels and COVID-19 Severity: A Systematic Review and Meta-Analysis
TLDR
Peripheral IFN-α cannot be used as a severity marker as it does not determine the clinical status presented by COVID-19 patients. Expand